Innate Pharma Stock Analysis

Innate Stock Analysis Notes

The company recorded a loss per share of 0.71. Innate Pharma had not issued any dividends in recent years. Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company was incorporated in 1999 and is headquartered in Marseille, France. Innate Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 213 people. To learn more about Innate Pharma call Mondher MD at 33 4 30 30 30 30 or check out https://www.innate-pharma.com.

Innate Pharma Investment Alerts

Innate Pharma Upcoming and Recent Events

Innate Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 180.17 M.

Innate Profitablity

The company has Profit Margin (PM) of (2.46) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.25) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $3.25.

Technical Drivers

As of the 23rd of July, Innate Pharma retains the Market Risk Adjusted Performance of 0.0708, downside deviation of 3.35, and Risk Adjusted Performance of 0.0153. Innate Pharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Innate Pharma Price Movement Analysis

Innate Pharma Outstanding Bonds

Innate Pharma Predictive Daily Indicators

Innate Pharma Forecast Models

Innate Pharma's time-series forecasting models are one of many Innate Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Innate Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Innate Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Innate shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Innate Pharma. By using and applying Innate Stock analysis, traders can create a robust methodology for identifying Innate entry and exit points for their positions.

When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.